IP Library Granted Patent US 10,709,362
Granted Patent B2
US 10,709,362 · App. 16/691,358 · Granted Jul 14, 2020

Analyte sensor

Inventors: Peter C. Simpson (Cardiff, CA); James H. Brauker (Coldwater, MI); Mark C. Brister (Eincinitas, CA); Paul V. Goode, Jr. (Round Rock, TX); Apurv Ullas Kamath (San Diego, CA); Aarthi Mahalingam (San Diego, CA); Jack Pryor (San Diego, CA); Matthew D. Wightlin (San Diego, CA)
Assignee: DexCom, Inc.
A61B5/14532A61B5/0002A61B5/0004A61B5/05A61B5/1411A61B5/1473A61B5/1486A61B5/1495A61B5/14503A61B5/14507A61B5/14514A61B5/14546A61B5/14735A61B5/14865A61B5/6801A61B5/6833A61B5/6848A61B5/6849A61B5/68335A61B5/72A61B17/3468A61B5/14A61B5/145A61B5/1468A61B5/150022A61B2017/3492A61B2560/0223A61B2560/045A61B2562/18A61M5/14244A61M5/1723A61M2005/1585Y02A90/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,709,362
App. No.
16/691,358
Granted
Jul 14, 2020
Kind
B2
Abstract

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

Claims (23)

1. A system for measuring a glucose concentration in a host, the system comprising:

a transcutaneous glucose sensor configured to provide sensor data indicative of a glucose concentration in a host;

sensor electronics configured to operatively connect to the transcutaneous analyte sensor; and

a processor configured to calibrate the sensor data based on predetermined calibration information, wherein the predetermined calibration information is obtained prior to implantation, wherein the predetermined calibration information is derived at least in part from a batch of sensors meeting a predetermined limit of sensor sensitivity variation, wherein the predetermined calibration information comprises one or both of predetermined baseline information and predetermined sensitivity information associated with the glucose sensor, and wherein the processor is configured to calibrate the sensor data without requiring reference data from a reference glucose monitor.

2. The system of claim 1 , wherein the calibration is based on a conversion function comprising a baseline value and a sensitivity value, and wherein the processor is configured to adjust the baseline value based on the predetermined baseline information.

3. The system of claim 1 , wherein the predetermined sensitivity information is derived from in vitro testing and is provided as a calibration code.

4. The system of claim 1 , further comprising:

a transmitter unit operably coupled to the glucose sensor, the transmitter unit having a radio frequency transmitter configured to wirelessly transmit sensor data; and

a receiver unit comprising a radio frequency receiver and a display, the radio frequency receiver configured to receive the transmitted sensor data and the display configured to display information based on the transmitted sensor data.

5. A method for processing data from a transcutaneous glucose sensor, the method comprising:

receiving sensor data from the transcutaneous glucose sensor after the transcutaneous glucose sensor is implanted in a host, wherein the sensor data is indicative of a glucose concentration in the host;

receiving predetermined calibration information, wherein the predetermined calibration information is derived at least in part from a batch of sensors meeting a predetermined limit of sensor sensitivity variation, wherein the predetermined calibration information comprises one or both of predetermined baseline information and predetermined sensitivity information associated with the transcutaneous glucose sensor; and

calibrating, using a processor, the sensor data received from the transcutaneous glucose sensor based at least in part on the predetermined calibration information, wherein the calibrating is performed without reliance on reference data from a reference glucose monitor.

6. The method of claim 5 , wherein the calibrating is based on a conversion function comprising a sensitivity value and a baseline value, and wherein the method further comprises validating the conversion function based on at least one of the predetermined baseline information or the predetermined sensitivity information.

7. The method of claim 6 , further comprising determining an error if the validation fails.

8. The method of claim 7 , further comprising adjusting the conversion function if the validation fails.

9. The method of claim 8 , wherein adjusting the conversion function comprises adjusting the baseline value of the conversion function.

10. The method of claim 9 , wherein adjusting the baseline value is based on the predetermined baseline information.

11. The method of claim 5 , wherein the predetermined sensitivity information is derived from in vitro testing and is provided as a calibration code.

12. The system of claim 1 , wherein the calibration is based on a conversion function comprising a baseline value and a sensitivity value, and wherein the processor is configured to validate the conversion function based on at least one of the predetermined sensitivity information or the predetermined baseline information.

13. The system of claim 12 , wherein the processor is configured to detect an error if the validation fails.

14. The system of claim 13 , wherein the processor is configured to adjust the conversion function if the validation fails.

15. The system of claim 14 , wherein the processor is configured to adjust the conversion function by adjusting the baseline value of the conversion function.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2020
From: GOODE, PAUL V., JR.; KAMATH, APURV ULLAS; MAHALINGAM, AARTHI; BRAUKER, JAMES H.
To: DEXCOM, INC.
Reel/Frame 052495/0243 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2020
From: MASTERSON, STEVE; SIMPSON, PETER; WIGHTLIN, MATTHEW D.; PRYOR, JACK; SWANSON, VANCE
To: DEXCOM, INC.
Reel/Frame 052301/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2020
From: BRISTER, MARK; PETISCE, JAMES R.; WOO, KUM MING; SAINT, SEAN; NOLTING, JOHN
To: DEXCOM, INC.
Reel/Frame 051848/0435 →
Continuity (6)
Continuation 16674610 · Nov 5, 2019
Continuation 16392521 · Apr 23, 2019
Continuation 14590483 · Jan 6, 2015
Continuation 13909962 · Jun 4, 2013
Continuation 11360262 · Feb 22, 2006
Related Publication 20200085350A1 · Mar 19, 2020
Cited By (7)
US 12,279,865 US 12,453,494 US 12,458,257 US 12,458,258 US 12,507,921 US 12,666,543 US 12,690,787